[Hypoxia-Inducible Factor Prolyl Hydroxylase Enzyme Inhibitors: A Novel Therapy for Anemia Treatment in CKD Patients].
Andrea Stucchi(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Mario Cozzolino(AOL (United States)), Anila Cara(University of Milan), Lorenza Magagnoli(AOL (United States))
PubMed
October 9, 2024
Cited by 0
Related Papers
37th International Symposium on Intensive Care and Emergency Medicine (part 2 of 3)
|Critical Care|2017|61
Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study
|Clinical Kidney Journal|2019|50
Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study
|Nephrology Dialysis Transplantation|2023|37
Choice of the Dialysis Modality: Practical Considerations
|Journal of Clinical Medicine|2023|30
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs
|Expert Opinion on Investigational Drugs|2024|24